PRODUCT LITERATURE

Glucose Tolerance: The STOP-NIDDM Trial Disease and Hypertension in Patients With Impaired Glucose Tolerance: The STOP-NIDDM Trial

---

Three hundred forty-one patients (24%) discontinued their participation prematurely, 211 in the acarbose-treated group and 130 in the placebo group; these patients were also followed up for outcome parameters. Decreasing postprandial hyperglycemia with acarbose was associated with a 49% relative risk reduction in the development of cardiovascular events (hazard ratio [HR], 0.51; 95% confidence interval [CI]; 0.28-0.95; P=.03) and a 2.5% absolute risk reduction

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Eclid

Specific Detail Info

JAMA. 2003;290(4):486-494

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment